Full-Time

Regional Business Director

Sunosi

Posted on 12/14/2024

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$170k - $205k/yr

+ Bonus + Equity

Senior

United States

Must live within the territory’s geography.

Category
Field Sales
Sales & Account Management
Required Skills
Sales
Requirements
  • BA or BS required. Advanced degree preferred
  • 5 years or more of field leadership experience and/or payer account management and/or demonstrated sales success with increasing responsibility and organizational leadership
  • Previous pharmaceutical, biotech, or medical marketing/sales experience preferred with at least three to five years spent in a position with demonstrated 1st line leadership groups
  • Proven performance history in the ability to lead others to success through your coaching influence
  • Demonstrated experience delivering outstanding results and developing others to their potential
  • Proven track record in attracting and retaining top talent
  • Current or recent sleep/CNS experience strongly preferred
  • Successful launch experience strongly preferred
  • Experience to strategize within teams using differential resources to reach business goals
  • Proven ability to run multiple tasks concurrently under aggressive timelines in a dynamic environment
  • Must live within the territory’s geography
  • Comfortable with uncertainty and high expectations
  • Patient support services experience a plus
  • Strong digital marketing aptitude
  • Strong interpersonal and presentation skills
Responsibilities
  • Responsible for supervising operations of the Region which includes: driving results, hiring and coaching, account manager development, performance management, and the assignment of key "priority" accounts within the medical community
  • Develop and implement strategic plans for the Region including the right balance of live/virtual interactions and the prioritization of efforts by the team
  • Plan, organize and drive performance to achieve the business potential of the region through coaching and influence of direct reports
  • Establish and maintain effective communication among all members of the Region across cross-channel stakeholders in the Accounts and Market Access team
  • Maintain required technical expertise in order to respond accurately to all questions regarding products, marketing, policies, and business-related issues from customers and account managers
  • Work with direct reports to understand and consistently execute established expectations
  • Consistently exemplify the ability to help a SAM improve on their selling skills, product knowledge and capabilities needed for success through coaching and counsel. Lead by example through coaching direct reports both in live and virtual engagements
  • Effectively plan and conduct plan of action and other meetings with members of the Region and Market Access teams
  • Develop and implement Region business plan, manage Region budget and overall responsibility for P&L at Region level in alignment with Regional and National expectations
  • Have a complete understanding of all relevant compliance laws, policies and processes and ensure actions of self and team are fully compliant
  • Overnight travel as indicated by the needs of the business
  • Additional responsibilities as assigned
Desired Qualifications
  • Patient support services experience a plus
  • Strong digital marketing aptitude
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, agitation from Alzheimer's disease, migraine, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist to help regulate mood. It has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's AXS-05 shows promise in treating major depressive disorder and treatment-resistant depression.
  • The company benefits from increased investment in mental health startups and partnerships.
  • FDA's support for fast-tracking CNS treatments aligns with Axsome's expedited drug development strategy.

What critics are saying

  • Increased competition in CNS disorder treatments could impact Axsome's market share.
  • Potential delays in clinical trials may postpone new product launches and affect revenue.
  • Dependence on a limited number of product candidates increases risk if they fail.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs in this area.
  • AXS-05, a flagship product, has FDA Breakthrough Therapy Designation for depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Life Care News
May 1st, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month.

Clival
Apr 8th, 2025
Axsome to Present Positive Phase 3 AXS-05 & AXS-12 Results at AAN 2025

Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced multiple presentations spanning its innovative, industry-leading psychiatry and neurology portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting, being held April 5-9 in San Diego, California.

Insider Monkey
Feb 23rd, 2025
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

INACTIVE